The diagnosis of latent, uncommon inflammations may have a great impact on the success of monitoring and treating many types of cancers. Ben-Neriah and his team are hard at work in the lab, developing tools for classifying the different types of inflammation and for understanding their development.
Further to his achievements in basic bio-medical research, Prof. Yinon Ben-Neriah has greatly contributed to translational medicine. Prof. Ben-Neriah and Prof. Alex Levitzki developed the first effective inhibitors of the Bcr-Abl protein, which eliminate chronic myeloid leukemia cells. These studies ultimately paved the way for the development of Gleevec, the flagship drug for treating CML disease. In addition to the abovementioned, Prof. Ben-Neriah and his team at the Hebrew University of Jerusalem Faculty of Medicine lab, are currently developing a new type of inhibitors, which target the protein phosphatase enzyme CKI, as a new form effective chemotherapy, particularly effective in treating acute leukemia.